{"publication_id":"3b9d2db0-4fb0-44d4-bab5-5c3b2794f100","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial","doi":"10.1016/j.bjane.2022.08.003","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-dose naltrexone’s utility for non-cancer centralized pain conditions: a scoping review","doi":"10.1093/pm/pnad074","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Low-Dose Naltrexone: What is the Evidence? A Narrative Review","doi":"10.1007/s12325-026-03612-5","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia","doi":"10.1016/j.heliyon.2023.e15638","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series","doi":"10.2147/JPR.S389957","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-dose naltrexone as an adjunctive treatment for major depressive disorder: findings from a randomized, double-blind, placebo-controlled hybrid parallel-arm study","doi":"10.3389/fphar.2026.1767654","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis","doi":"10.3344/kjp.24202","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Effective Doses of Low-Dose Naltrexone for Chronic Pain – An Observational Study","doi":"10.2147/JPR.S451183","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis","doi":"10.3390/biomedicines11041087","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19","doi":"10.1016/j.bbih.2024.100733","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems","doi":"10.1371/journal.pone.0297948","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-Dose Naltrexone for Managing Pain and Autonomic Symptoms in Patients With Dysautonomia","doi":"10.7759/cureus.86538","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"No change in the consumption of thyroid hormones after starting low dose naltrexone (LDN): a quasi-experimental before-after study","doi":"10.1186/s12902-020-00630-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study","doi":"10.1136/bmjopen-2021-058358","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment","doi":"10.3389/fimmu.2021.687806","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial","doi":"10.1186/s13063-021-05776-7","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Efficacy and safety of low-dose naltrexone (LDN) in fibromyalgia: a systematic review and meta-analysis","doi":"10.1097/MS9.0000000000003203","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost–utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)","doi":"10.1136/bmjopen-2021-055351","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia","doi":"10.1136/bmjopen-2024-085272","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study","doi":"10.1097/PR9.0000000000001080","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder","doi":"10.1186/s13063-022-06738-3","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Extemporaneous Preparation and Effectiveness of Low-Dose Naltrexone for the Treatment of Uremic Pruritus: A Literature Review and Case Report","doi":"10.3390/pharmacy13060160","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review","doi":"10.2147/JPR.S395457","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up","doi":"10.7759/cureus.83824","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-dose naltrexone as a treatment for vulvodynia: A case series","doi":"10.1016/j.crwh.2024.e00677","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-dose naltrexone as a treatment for chronic fatigue syndrome","doi":"10.1136/bcr-2019-232502","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"190. EFFECTS OF LOW-DOSE NALTREXONE ON SALIENCE NETWORK CONNECTIVITY IN MAJOR DEPRESSIVE DISORDER","doi":"10.1093/ijnp/pyaf052.176","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Improvement in Hailey–Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: A case report","doi":"10.1177/2050313X20984121","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Unexpected Increase in Bone Mineral Density With Rapamycin and Low-Dose Naltrexone: A Case Report of a 52-Year-Old Woman With Osteopenia","doi":"10.7759/cureus.77435","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-Dose Naltrexone in Chronic Pain Management: Mechanisms, Evidence, and Clinical Implications","doi":"10.3390/jpm16030151","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review","doi":"10.7759/cureus.81086","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Low-Dose Naltrexone in Rheumatological Diseases","doi":"10.31138/mjr.34.1.1","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-Dose Naltrexone Use in Postural Orthostatic Tachycardia Syndrome: A Case Series","doi":"10.7759/cureus.43426","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy","doi":"10.3390/cancers16061240","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Is low-dose naltrexone effective in chronic pain management?","doi":"10.12788/jfp.0654","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study","doi":"10.1093/ecco-jcc/jjy008","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization","doi":"10.3390/medsci6040082","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia","doi":"10.3390/biomedicines5020016","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Low-Dose Naltrexone for Pruritus in Systemic Sclerosis","doi":"10.1155/2011/804296","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Ioannidis 2005","doi":"10.1371/journal.pmed.0020124","risk_of_bias":"not appraised in public sidecar","directness":"citation"}]}